Research and Markets: Key Process Patents for Erythropoietin Expired in Europe and th

Nika · #1 (**permalink**) 05-05-2005, 07:49 PM

May 3, 2005

Source:
PR Newswire

Research and Markets: Key Process Patents for Erythropoietin Expired in Europe and the US in Late 2004 Opening the Market for Potential Generic Competition

DUBLIN, Ireland, May 3 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/reports/c16767 ) has announced the addition of Erythropoietin Current Market Dynamics & Future Outlook to their offering.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH )

At the end of 2004 the world market for erythropoietin was valued at $11.1 billion, a growth of 8% over 2003. The market has been growing at an average annual growth rate of 18% over the previous 5 years.

The market for Erythropoietin is very lucrative. Marketing costs are low due to the well-defined patient population and distribution costs are low due to the limited distribution outlets. Since the market is a virtual oligopoly barriers to entry are high thus insuring high profitability.

Key process patents for Erythropoietin expired in Europe and the US in late 2004 opening the market for potential generic competition. Already generic products have been developed and are currently being marketed in Asia, Latin America and Eastern Europe.

With such a huge market at stake both large multinationals such as Novartis's Sandoz biogenerics division and large generics producers such as Ratiopharm of Germany are eyeing the market.

Many new and emerging dedicated biogenerics companies have launched their products in selected niche markets and many licensing opportunities for fully developed generics versions of epoetin alfa are available for the taking.

Written with the senior executive needs in mind, Erythropoietin - Current Market Dynamics & Future outlook, is a must read for pharmaceutical and medical biotech professionals interested in high growth area therapeutics or in Biogenerics.

Contents contained inside this report include:-
Executive Briefing
State of the Science
Overview
The Process of Erythropoiesis
Structure, Production & Function Erythropoietin
Darbepoetin
Clinical Applications of Erythropoietin
Role of Erythropoietin in Chronic Renal Failure
Role of Erythropoietin in Chemotherapy Treated Cancer Patients
Role of Erythropoietin in AZT Treated AIDS Patients
Role of Erythropoietin in Surgery
The Erythropoietin Receptors
(EpoR) Erythropoietin Small Molecule Mimics
Clinical & Cost Effectiveness Controversies
Market Size & Growth Rates
The World Market for Erythropoietin
The North American Market for Erythropoietin
The European Markets for Erythropoietin
The Japanese Market for Erythropoietin
Companies & Products
Overview
Historical Perspective
Dosage & Formulations
Recombinant Erythropoietin
Aranesp (darbepoetin alfa)
Decision Making & Dispensing Dynamics
Present Pricing Strategy
Reimbursement Status
Key Patents Expiry Dates
Epoetin Alfa Key Patents Expiry Dates
Darbepoetin Alfa Key Patents Expiry Dates
Products & Companies Market Shares
Leading Companies & Their Products
Amgen
Epogen (Epoetin Alfa)
Aranesp (Darbepoetin Alfa)
Johnson & Johnson
Procrit / Eprex / Erypo (Epoetin Alfa)
Roche / Chugai
NeoRecormon (Epoetin Beta)
Epogin (Epoetin Beta)
Kirin Espo (Epoetin Alfa)
Other Participants in the Market
Baxter International
Dragon Pharmaceuticals
CIGB-HEBER
Potential New Entrants into the Market
Affymax
Aventis
Barr Pharmaceuticals
Fuso Pharmaceutical Industries
GeneMedix
Mayne Pharma
Novartis / Sandoz
Pliva Ratiopharm / BioGeneriX
Country Based Erythropoietin Production Initiatives
China
Cuba
India
Iran
Strategic Opportunities
Market Attractiveness
Opportunities in New Product Development
Opportunities in Product Synergy
Opportunities in Super Generics
The Shape of the Market to Come
Main Vectors of Change
Patient Pool Trends
Product Pricing Trends
Erythropoietin Market Forecasts (2004 - 2010)
The Market in 2010
For more information visit http://www.researchandmarkets.com/reports/c16767

Laura Wood Senior Manager Research and Markets press@researchandmarkets.com Fax: +353 1 4100 980

Thread Tools	Search this Thread
Show Printable Version Email this Page	Search this Thread: Advanced Search
Display Modes	Rate This Thread
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode	Rate This Thread:

Similar Threads
Thread	Thread Starter	Forum	Replies	Last Post
MIRCERA Receives Positive Opinion in Europe for the Treatment of Anaemia	Sharon Grant	News and Hot Topics such as Hepatitis C, SARS and AIDS	0	05-29-2007 09:13 PM
Genomics and blood substitutes for 21st century Europe ("EuroBloodSubstitutes").	Sharon Grant	Medical Articles and Abstracts	0	12-15-2006 09:19 PM
Europe: Big increase in HIV-positive blood donors sparks fears	Nika	News and Hot Topics such as Hepatitis C, SARS and AIDS	1	04-25-2005 12:37 AM
Thrombocythaemia Research	markejon	General Discussions	1	01-27-2004 10:28 AM
Thrombocythaemia Research	markejon	Ask a Professional	0	01-26-2004 04:51 PM

Research and Markets: Key Process Patents for Erythropoietin Expired in Europe and th

Welcome to the latest in bloodless medicine and blood transfusion alternatives.

We are a community of medical professionals and members of the public who are responding to the worldwide concern about the efficacy, cost and availability of donor blood.

Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)